| abstract |
This invention relates to a new process for the preparation of Form V of crystalline lercanidipine ∙ HCl. The method includes (i) crystallizing from a mixture of iPrOAc and a non-proton polar organic solvent such as ACN, MeCO, DMF or DMA, or (ii) suspending lercanidipine ∙ HCl in iPrOAc. More specifically, crystalline lercanidipine ∙ HCl, preferably Form I, is usually dissolved in DMF or DMA, while amorphous lercanidipine ∙ HCl is usually dissolved in ACN or acetone. When lercanidipine ∙ HCl is suspended in iPrOAc, this is advantageously carried out using amorphous lercanidipine ∙ HCl. |